NCT01933061View on ClinicalTrials.gov

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Metastatic Melanoma
Interventions
DRUG

Abraxane

Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle

DRUG

Abraxane

Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY

NCT01933061 - Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | Biotech Hunter | Biotech Hunter